Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
By F. Polack, Stephen J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, John L. Perez, Gonzalo Pérez Marc, E. Moreira, C. Zerbini and 19 more. New England Journal of Medicine, 2020
11,263 citations recorded by the source corpus.
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)
Subfields: Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/b47e6e19e7c459210316ee02b830253fe8a6e904
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Molecular Biology
- K. H. Crawford
- J. Kulkarni
- I. Frank
- Alessandro Sette
- Min Wu
- Camilla Hald Albertsen
- Alba Grifoni
- K. Petersson
Citations in the corpus
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity (2021, neutral): “Both of these vaccines demonstrated >94% efficacy at preventing coronavirus disease 2019 (COVID-19) in phase III clinical studies performed in late 2020 in multiple countries (Polack et al. 2020; Baden et al. 2021).”
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021, neutral): “Finally, protective mRNA- and vector-based vaccines encoding the SARS-CoV-2 S protein have been approved for human use and are considered key to the containment of the COVID-19 pandemic (Baden et al., 2021; Polack et al., 2020).”
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study (2021, neutral): “SARS-CoV-2 quantitative RT-PCR, conversion of ORF1ab and envelope (E-gene) cycle threshold values to viral genome copies, whole-genome sequencing, and lineage assignments are described in the appendix (pp 13–14).”
- mRNA-based therapeutics: powerful and versatile tools to combat diseases (2022, background): “mutation of two proline residues of the spike protein to stabilize it in the prefusion conformation, and BNT162b2 and mRNA-1273 both used 1-methyl-3′-pseudouridylyl modified mRNA (m1Ψ mRNA) encoding prefusion S protein.(271,279) SARS-CoV-2 spike RBD, as the binding site for hACE2, facilitates virus ”
- Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study (2021, neutral): “3,7 Similarly, rates of side-effects following the ChAdOx1 nCoV-19 vaccine were lower than expected.”